Male breast cancer. A report of 71 cases

Omari-Alaoui, H El; Lahdiri, I.; Nejjar, I.; Hadadi, Khalid; Ahyoud, F; Hachi, Hafid; Alhilal, M.; Errihani, Hassan; Benjaafar, Noureddine; Souadka, Amine; Gueddari, B.K. El

doi:10.1016/s1278-3218(02)00250-0

Cited by 28 publications

(20 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More than 90% of male breast cancer cases are infiltrative ductal carcinomas [1][2][3][4][5] , with 80%-90% expressing the estrogen receptor and 65%-92% expressing the progesterone receptor 3,4,[6][7][8] . Given this receptor profile, endocrine therapy is often prescribed in this patient population.…”

Section: Introductionmentioning

confidence: 99%

Endocrine Therapy for Male Breast Cancer: Rates of Toxicity and Adherence

2010

View full text Add to dashboard Cite

Purpose: Most male breast cancer tumours are hormone receptor–positive; the patients therefore receive endocrine therapy. There is, however, a paucity of published data on toxicities experienced by male breast cancer patients who are prescribed endocrine therapy. In the present study, we examined rates of adherence to and toxicity from endocrine treatments in male breast cancer patients treated at a single institution. Patients and Methods: We conducted a retrospective study of male patients diagnosed with breast cancer at The Ottawa Hospital Cancer Centre during 1981–2003. Data collected included patient age, hormone receptor status, therapy adherence, self-reported toxicities, and type and duration of endocrine therapies. Results: The review located 59 cases of early-stage and metastatic male breast cancer. Median patient age was 68.0 years. Tamoxifen was given to 38 patients (64.4%), anastrozole to 8 (13.6%), and letrozole to 5 (8.5%). Of patients who received endocrine therapy, 10 (25%) received adjuvant systemic chemotherapy. Toxicity was reported by 19 patients taking tamoxifen (50%), with hot flashes being the most common complaint (18.4%). Decreased libido, weight gain, and malaise were reported by 5 patients (13.2%). Rash and erectile dysfunction were reported by 3 patients (7.9%). Increased liver enzymes, pulmonary embolism, superficial thrombophlebitis, myalgia, depression, visual blurring, and loose stools were each reported in 1 patient (2.6%). Tamoxifen therapy was discontinued secondary to toxicity in 9 patients (23.7%). Of the patients treated with anastrozole, 3 (37.5%) reported toxicity, with 1 report each of decreased libido, leg swelling, and depression (12.5%). Toxicity was reported in 2 patients taking letrozole (40%), with both reporting peripheral edema, and 1 reporting hot flashes. No patient discontinued anastrozole or letrozole because of toxicity. Conclusions: Few studies specifically report data on adherence to and toxicities from endocrine therapies in male breast cancer patients. The rate of discontinuation at our institution because of toxicity (23.7%) is similar to that reported in the female breast cancer population. Future prospective studies should explore strategies to improve adherence to endocrine therapy in this population.

show abstract

Section: Introductionmentioning

confidence: 99%

Endocrine Therapy for Male Breast Cancer: Rates of Toxicity and Adherence

2010

View full text Add to dashboard Cite

show abstract

“…[37][38][39]53,[79][80][81] Nipple discharge is a presenting symptom in 5% to 15% of men, 37,53 whereas skin ulceration is demonstrated in 7% to 10%. 37,53 Paget's disease is present in only 5% of cases.…”

Section: What Are the Clinical Features Of Male Breast Cancer?mentioning

confidence: 99%

“…29,39,56,85 The median duration of symptoms before diagnosis varies between 9 and 18 weeks in the United States, 36,37,78 whereas a longer time from the onset of symptoms to diagnosis is reported in other countries. 38,39,80,81 In the United States, the median age at diagnosis ranges from 58 to 65 years. 36,37,55,79 What is the appropriate workup of male breast enlargement?…”

Section: What Are the Clinical Features Of Male Breast Cancer?mentioning

confidence: 99%

Treatment of Male Breast Cancer

Murphy¹,

Borgen²

2005

Breast Cancer

View full text Add to dashboard Cite

“…MBC tends to be diagnosed at a later stage than breast cancer in females, largely because of the public's lack of awareness about the disease in men (El Omari-Alaoui et al, 2002;Giordano et al, 2002). Similar to female breast cancer, the most important prognostic indicators for MBC are tumor size, axillary node status, ER and PR status, and histologic grade (El Omari-Alaoui et al; Giordano et al).…”

Section: Prognosismentioning

confidence: 99%